Basilea Pharmaceutica AG (SIX: BSLN.SW) Stock Competitors & Peer Comparison
See BSLN.SW's competitors and their performance on the SIX and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BSLN.SW and its SIX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BSLN.SW | CHF 64.60 | -1.52% | 799.5M | 30.60 | CHF 2.11 | N/A |
| LONN.SW | CHF 592.20 | +1.09% | 41.4B | 37.18 | CHF 15.93 | +0.84% |
| BANB.SW | CHF 77.40 | +0.00% | 5.8B | 38.93 | CHF 1.99 | +1.16% |
| MOR.SW | CHF 102.00 | +0.00% | 2.4B | -4.03 | -CHF 25.33 | N/A |
| IDIA.SW | CHF 5.55 | -0.89% | 1.5B | -6.41 | -CHF 0.87 | N/A |
| KURN.SW | CHF 21.52 | -4.19% | 848.7M | 118.90 | CHF 0.18 | N/A |
| NWRN.SW | CHF 12.54 | -0.32% | 260.9M | 18.57 | CHF 0.68 | N/A |
| SANN.SW | CHF 16.64 | +0.73% | 246.8M | -4.34 | -CHF 3.83 | N/A |
| MOLN.SW | CHF 3.49 | +0.00% | 130.9M | -2.24 | -CHF 1.56 | N/A |
| RLF.SW | CHF 2.89 | +0.87% | 36.3M | -2.12 | -CHF 1.36 | N/A |
Stock Comparison
Lonza Group AG (SIX: LONN.SW)
BSLN.SW vs LONN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, LONN.SW has a market cap of 41.4B. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while LONN.SW trades at CHF 592.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas LONN.SW's P/E ratio is 37.18. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to LONN.SW's ROE of -0.01%. Regarding short-term risk, BSLN.SW is more volatile compared to LONN.SW. This indicates higher risk in terms of short-term price fluctuations for BSLN.SW.Check LONN.SW's competition here
Bachem Holding AG (SIX: BANB.SW)
BSLN.SW vs BANB.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, BANB.SW has a market cap of 5.8B. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while BANB.SW trades at CHF 77.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas BANB.SW's P/E ratio is 38.93. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to BANB.SW's ROE of +0.10%. Regarding short-term risk, BSLN.SW is more volatile compared to BANB.SW. This indicates higher risk in terms of short-term price fluctuations for BSLN.SW.Check BANB.SW's competition here
MorphoSys AG (SIX: MOR.SW)
BSLN.SW vs MOR.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, MOR.SW has a market cap of 2.4B. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while MOR.SW trades at CHF 102.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas MOR.SW's P/E ratio is -4.03. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to MOR.SW's ROE of -1.84%. Regarding short-term risk, BSLN.SW is not fully comparable compared to MOR.SW. This indicates unavailable risk data in terms of short-term price fluctuations for BSLN.SW.Check MOR.SW's competition here
Idorsia Ltd (SIX: IDIA.SW)
BSLN.SW vs IDIA.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, IDIA.SW has a market cap of 1.5B. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while IDIA.SW trades at CHF 5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas IDIA.SW's P/E ratio is -6.41. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to IDIA.SW's ROE of +0.27%. Regarding short-term risk, BSLN.SW is less volatile compared to IDIA.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check IDIA.SW's competition here
Kuros Biosciences AG (SIX: KURN.SW)
BSLN.SW vs KURN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, KURN.SW has a market cap of 848.7M. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while KURN.SW trades at CHF 21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas KURN.SW's P/E ratio is 118.90. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to KURN.SW's ROE of +0.10%. Regarding short-term risk, BSLN.SW is more volatile compared to KURN.SW. This indicates higher risk in terms of short-term price fluctuations for BSLN.SW.Check KURN.SW's competition here
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW)
BSLN.SW vs NWRN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, NWRN.SW has a market cap of 260.9M. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while NWRN.SW trades at CHF 12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas NWRN.SW's P/E ratio is 18.57. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to NWRN.SW's ROE of +2.78%. Regarding short-term risk, BSLN.SW is more volatile compared to NWRN.SW. This indicates higher risk in terms of short-term price fluctuations for BSLN.SW.Check NWRN.SW's competition here
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW)
BSLN.SW vs SANN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, SANN.SW has a market cap of 246.8M. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while SANN.SW trades at CHF 16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas SANN.SW's P/E ratio is -4.34. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to SANN.SW's ROE of +6.85%. Regarding short-term risk, BSLN.SW is less volatile compared to SANN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check SANN.SW's competition here
Molecular Partners AG (SIX: MOLN.SW)
BSLN.SW vs MOLN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, MOLN.SW has a market cap of 130.9M. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while MOLN.SW trades at CHF 3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas MOLN.SW's P/E ratio is -2.24. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to MOLN.SW's ROE of -0.66%. Regarding short-term risk, BSLN.SW is more volatile compared to MOLN.SW. This indicates higher risk in terms of short-term price fluctuations for BSLN.SW.Check MOLN.SW's competition here
Relief Therapeutics Holding AG (SIX: RLF.SW)
BSLN.SW vs RLF.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, RLF.SW has a market cap of 36.3M. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while RLF.SW trades at CHF 2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas RLF.SW's P/E ratio is -2.12. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to RLF.SW's ROE of -0.39%. Regarding short-term risk, BSLN.SW is less volatile compared to RLF.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check RLF.SW's competition here
MindMaze Therapeutics Holding S.A. (SIX: MMTX.SW)
BSLN.SW vs MMTX.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, MMTX.SW has a market cap of 29.9M. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while MMTX.SW trades at CHF 0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas MMTX.SW's P/E ratio is -0.40. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to MMTX.SW's ROE of N/A. Regarding short-term risk, BSLN.SW is less volatile compared to MMTX.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check MMTX.SW's competition here
Addex Therapeutics Ltd (SIX: ADXN.SW)
BSLN.SW vs ADXN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, ADXN.SW has a market cap of 5.3M. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while ADXN.SW trades at CHF 0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas ADXN.SW's P/E ratio is -0.62. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to ADXN.SW's ROE of -1.31%. Regarding short-term risk, BSLN.SW is less volatile compared to ADXN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check ADXN.SW's competition here
Spexis AG (SIX: SPEX.SW)
BSLN.SW vs SPEX.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, SPEX.SW has a market cap of 3.9M. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while SPEX.SW trades at CHF 0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas SPEX.SW's P/E ratio is -0.15. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to SPEX.SW's ROE of N/A. Regarding short-term risk, BSLN.SW is less volatile compared to SPEX.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check SPEX.SW's competition here
ObsEva S.A. (SIX: OBSN.SW)
BSLN.SW vs OBSN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, OBSN.SW has a market cap of 140.6K. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while OBSN.SW trades at CHF 0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas OBSN.SW's P/E ratio is -0.00. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to OBSN.SW's ROE of -1.46%. Regarding short-term risk, BSLN.SW is less volatile compared to OBSN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check OBSN.SW's competition here
Polyphor AG (SIX: POLN.SW)
BSLN.SW vs POLN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, POLN.SW has a market cap of 0. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while POLN.SW trades at CHF 1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas POLN.SW's P/E ratio is -0.46. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to POLN.SW's ROE of -1.32%. Regarding short-term risk, BSLN.SW is less volatile compared to POLN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check POLN.SW's competition here
Cassiopea S.p.A. (SIX: SKIN.SW)
BSLN.SW vs SKIN.SW Comparison August 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 799.5M. In comparison, SKIN.SW has a market cap of 0. Regarding current trading prices, BSLN.SW is priced at CHF 64.60 on the SIX, while SKIN.SW trades at CHF 35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 30.60, whereas SKIN.SW's P/E ratio is -28.13. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to SKIN.SW's ROE of -1.27%. Regarding short-term risk, BSLN.SW is less volatile compared to SKIN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check SKIN.SW's competition here